Bristol-Myers (BMY) Acquires Inhibitex (INHX) at 163% Premium
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Join SI Premium – FREE
Late Saturday, Bristol-Myers Squibb Company (NYSE: BMY) announced a definitive agreement to acquire Inhibitex, Inc. (Nasdaq: INHX) for $26.00 per share in cash, or approximately $2.5 billion.
The offer comes at a 163 percent premium to Inhibitex's closing price of $9.87 on Friday.
Inhibitex's lead HCV asset is INX-189, an oral nucleotide polymerase (NS5B) inhibitor in Phase II development that has exhibited potent antiviral activity, a high barrier to resistance and pan-genotypic coverage.
"The acquisition of Inhibitex builds on Bristol-Myers Squibb's long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company."
The transaction is expected to be dilutive to earnings for Bristol-Myers Squibb through 2016, with an expected impact on earnings per share of approximately $0.04 in 2012 and approximately $0.05 in 2013.
The offer comes at a 163 percent premium to Inhibitex's closing price of $9.87 on Friday.
Inhibitex's lead HCV asset is INX-189, an oral nucleotide polymerase (NS5B) inhibitor in Phase II development that has exhibited potent antiviral activity, a high barrier to resistance and pan-genotypic coverage.
"The acquisition of Inhibitex builds on Bristol-Myers Squibb's long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company."
The transaction is expected to be dilutive to earnings for Bristol-Myers Squibb through 2016, with an expected impact on earnings per share of approximately $0.04 in 2012 and approximately $0.05 in 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deutsche Bank monitors UK auto sales as Chinese exports grow
- Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Hot List, Hot M&A, Mergers and AcquisitionsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
